Neurostimulation for Parkinson's disease with early motor complications

Item does not contain fulltextBACKGROUND: Subthalamic stimulation reduces motor disability and improves quality of life in patients with advanced Parkinson's disease who have severe levodopa-induced motor complications. We hypothesized that neurostimulation would be beneficial at an earlier stage of Parkinson's disease. METHODS: In this 2-year trial, we randomly assigned 251 patients with Parkinson's disease and early motor complications (mean age, 52 years; mean duration of disease, 7.5 years) to undergo neurostimulation plus medical therapy or medical therapy alone. The primary end point was quality of life, as assessed with the use of the Parkinson's Disease Questionnaire (PDQ-39) summary index (with scores ranging from 0 to 100 and higher scores indicating worse function). Major secondary outcomes included parkinsonian motor disability, activities of daily living, levodopa-induced motor complications (as assessed with the use of the Unified Parkinson's Disease Rating Scale, parts III, II, and IV, respectively), and time with good mobility and no dyskinesia. RESULTS: For the primary outcome of quality of life, the mean score for the neurostimulation group improved by 7.8 points, and that for the medical-therapy group worsened by 0.2 points (between-group difference in mean change from baseline to 2 years, 8.0 points; P=0.002). Neurostimulation was superior to medical therapy with respect to motor disability (P<0.001), activities of daily living (P<0.001), levodopa-induced motor complications (P<0.001), and time with good mobility and no dyskinesia (P=0.01). Serious adverse events occurred in 54.8% of the patients in the neurostimulation group and in 44.1% of those in the medical-therapy group. Serious adverse events related to surgical implantation or the neurostimulation device occurred in 17.7% of patients. An expert panel confirmed that medical therapy was consistent with practice guidelines for 96.8% of the patients in the neurostimulation group and for 94.5% of those in the medical-therapy group. CONCLUSIONS: Subthalamic stimulation was superior to medical therapy in patients with Parkinson's disease and early motor complications. (Funded by the German Ministry of Research and others; EARLYSTIM ClinicalTrials.gov number, NCT00354133.)

Determination of the number of J/ψ events with inclusive J/ψ decays

A measurement of the number of J/ψ events collected with the BESIII detector in 2009 and 2012 is performed using inclusive decays of the J/ψ. The number of J/ψ events taken in 2009 is recalculated to be (223.7 ± 1.4) × 106, which is in good agreement with the previous measurement, but with significantly improved precision due to improvements in the BESIII software. The number of J/ψ events taken in 2012 is determined to be (1086.9 ± 6.0) × 106. In total, the number of J/ψ events collected with the BESIII detector is measured to be (1310.6 ± 7.0) × 106, where the uncertainty is dominated by systematic effects and the statistical uncertainty is negligible

Measurements of the center-of-mass energies at BESIII via the di-muon process

From 2011 to 2014, the BESIII experiment collected about 5 fb-1 data at center-of-mass energies around 4 GeV for the studies of the charmonium-like and higher excited charmonium states. By analyzing the di-muon process e+e- → γISR/FSRμ+μ-, the center-of-mass energies of the data samples are measured with a precision of 0.8 MeV. The center-of-mass energy is found to be stable for most of the time during data taking

Measurement of the absolute branching fraction for Λc+→Λμ+νμ

We report the first measurement of the absolute branching fraction for Λc+→Λμ+νμ. This measurement is based on a sample of e+e− annihilation data produced at a center-of-mass energy s=4.6 GeV, collected with the BESIII detector at the BEPCII storage rings. The sample corresponds to an integrated luminosity of 567 pb−1. The branching fraction is determined to be B(Λc+→Λμ+νμ)=(3.49±0.46(stat)±0.27(syst))%. In addition, we calculate the ratio B(Λc+→Λμ+νμ)/B(Λc+→Λe+νe) to be 0.96±0.16(stat)±0.04(syst)

Nematóides do Brasil 2ª parte: nematóides de anfíbios Brazilian nematodes - part 2: nematodes of amphibians

São reunidas neste trabalho todas as espécies de nematóides parasitas de anfíbios encontradas no Brasil, com dados suficientes para a sua identificação especifica. Na primeira parte que é o catálogo dos nematóides parasitos de anfíbios, são relacionadas nove superfamilias, quatorze famílias, vinte e quatro gêneros e sessenta e três espécies, sendo que destas, são dadas figuras e medidas. Na segunda parte que é o catálogo dos anfíbios hospedeiros, todos pertencentes à ordem Anura, são referidas seis famílias e cinqüenta e cinco espécies de anfíbios, estas com os nematóides respectivos. A identificação dos nematóides é auxiliada por chaves de determinação das superfamílias, famílias e gêneros, sendo a identificação específica feita através de quadros de medidas e figuras.<br>A survey of nematode species parasitizing Brazilian amphibians is presented, with data enough to provide their specific identification. The first section refers to the catalogation of the species, related to 9 superfamilies, 14 families, 24 genera and 63 species that are figurated and included in measurement tables. The second section is concerned to the catalogue of host amphibians of the order Anura, with 6 families, and 55 species and their respective parasite nematodes. The identification of these helminths is achieved by means of keys to the superfamilies, families and genera. Specific determination is induced through the figures and tables as above mentioned